CYP19A1 and prostate cancer: By establishing clinically relevant in vitro bioassays for breast cancer (AroER Tri-Screen assay) and prostate cancer (LNCaP-PSA luciferase assay), we have shown that WBM extracts significantly inhibit aromatase activity and ER activation in breast cancer cells [180], and also interrupt the AR activation and PSA expression in prostate cancer cells [184].